Antiestrogen ICI 182, 780 decreases proliferation of insulin-like growth factor I (IGF-I)-treated MCF-7 cells without inhibiting IGF-I signaling

Cancer Research

Volumn 62, Issue 14, 2002, Pages 3985-3991

  Varma, Hemant ^a   Conrad, Susan E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN D1; ESTROGEN RECEPTOR; FULVESTRANT; INSULIN RECEPTOR SUBSTRATE 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL DIVISION; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0037099717     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation
2. Regulation of breast cancer growth by insulin-like growth factors
3. Phosphoinositide 3-kinase: The key switch mechanism in insulin signalling
4. The IRS-signalling system: A network of docking proteins that mediate insulin action
5. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase
6. 1 arrest followed by cell death
7. Protein kinases as mediators of phosphoinositide 3-kinase signaling
8. D-type cyclins
9. The multifaceted mechanisms of estradiol and estrogen receptor signaling
10. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma
11. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture
12. Estrogens and cell-cycle regulation in breast cancer
13. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens
14. Inhibition of growth-factor-activated proliferation by anti-estrogens and effects on early gene expression of MCF-7 cells
15. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells
16. Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780
17. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line
18. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells
19. Laminin inhibits estrogen action in human breast cancer cells
20. Activation of Akt/protein kinase B by G protein-coupled receptors. A role for α and β γ subunits of heterotrimeric G proteins acting through phosphatidylinositol-3-OH kinase γ
21. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase
22. Mutational analysis of cysteine residues within the hormone-binding domain of the human estrogen receptor identifies mutants that are defective in both DNA-binding and subcel]ular distribution
23. A simple, rapid, and sensitive DNA assay procedure
24. D-type cyclin-dependent kinase activity in mammalian cells
25. Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain
26. Cancer cell cycles
27. Antiestrogen ICI 164.384 reduces cellular estrogen receptor content by increasing its turnover
28. Regulation of the estrogen receptor in MCF-7 cells by estradiol
29. Estradiol regulates estrogen receptor mRNA stability
30. Progesterone and the progesterone receptor
31. Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells
32. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components
33. WAF1/CIP1
34. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
35. Akt activation by growth factors is a multiple-step process: The role of the PH domain
36. Activation of the c-fos serum response element by phosphatidylinositol 3-kinase and rho pathways in HeLa cells
37. SRF-dependent gene expression is required for P13-kinase-regulated cell proliferation
38. Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vitro
39. Role of AKT1 in 17β-estradiol- and insulin-like growth factor I (IGF- I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells
40. P13-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 ceils
41. Estrogen-induced mitogenesis of MCF-7 cells does not require the induction of mitogen-activated protein kinase activity
42. Paradoxical effects of overexpression of the type I insulin-like growth factor (IGF) receptor on the responsiveness of human breast cancer cells to IGFs and estradiol
43. Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182.780 in breast cancer cells
44. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: A new model for anti-estrogen resistance
45. Insulin receptor expression and function in human breast cancer cell lines
46. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway
47. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution
48. t-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2
49. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry
50. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence
51. Multifaceted regulation of cell cycle progression by estrogen: Regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function
52. WAF1/CIP1 is an antiesrrogen-regulated inhibitor of Cdk4 in human breast cancer cells